Supportive and Palliative Care Research

Word cloud containing Symptom Science topics.The program supports studies on the prevention or treatment of acute and chronic symptoms and morbidities related to cancer and its treatment. This includes the impact on the quality of life of patients and their informal caregivers. The program also supports studies of patients and their caregivers at the end of life.

Read more About the Supportive and Palliative Care Research

Pre-Application Webinars for RFA-CA-17-052Cover slide for RFA-CA-17-52.

"Analyzing and Interpreting Clinician and Patient Adverse Event Data to Better Understand Tolerability (U01)"

NCI Listens — Slides Available

Cancer Moonshot Blue Ribbon PanelMaterials are now available from NCI Listens: Identifying Opportunities for Symptom Management Research in Response to Blue Ribbon Report (PPT, 1.44MB), a webinar lead by Dr. Ann O’Mara, Head, Palliative Care Research in the Division of Cancer Prevention (DCP), and other DCP staff, DCP was interested in hearing from the extramural research and patient advocate community regarding knowledge gaps and priorities for symptom management research, particularly as it pertains to understanding the mechanisms of cancer and treatment related symptoms and adverse events/toxicities that patients report when enrolled in clinical trials.

Topic Areas (more to come)

Anorexia, Cachexia, Cardiotoxicity, Caregiver Issues, Cognitive Dysfunction, Distress/Anxiety/Depression, End of Life, Fatigue, Geriatrics, Hot Flashes, Lymphedema, Medication Adherence, Mucositis, Multiple Symptoms, Musculoskeletal Symptoms, Nausea, Neuropathy, Nutrition, Oral Complications, Other Supportive Care Issues, Pain, Palliative Care, Pediatrics/Adolescents/Young Adult, Physical Functioning, Quality of Life, Skin Toxicities, Sleep Disorders, Urinary Complications

When tumors metastasize to the bone (orange), osteoclasts (red) promote the breakdown of bone and promote the growth of cancer cells (blue).Feature Article

Less-Frequent Zoledronic Acid Treatment Effective at Preventing Bone Metastasis Complications

In a clinical trial involving patients with metastatic cancer, administration of zoledronic acid every 12 weeks was as effective at preventing skeletal-related events caused by bone metastases as administration every 4 weeks.

POSTED: 01/30/2017
NCI Cancer Currents

Read the article

An echocardiogram showing a measurement of the heart's left ventricle.
An echocardiogram showing a measurement of the heart's left ventricle
Credit: Wikimedia Commons

Feature Article

Treating Cancer without Harming the Heart

More people are living longer after a diagnosis of cancer than at any time in the past. This is the result, in part, of new therapies and strategies for treating cancer. But some of the same treatments that help people survive cancer may also damage the heart and lead to cardiovascular problems, including hypertension, cardiac arrhythmia, and heart failure.

Read more